Media Type: eBook
Availability: In stock
Retinoblastoma is a rare and unique malignancy. Its incidence is approximately 1 in 18,000 live births in the United States and it accounts for 3% of all pediatric cancers. It’s estimated that up to 8,000 cases occur annually worldwide. Left untreated, retinoblastoma is nearly uniformly fatal. However, in parts of the world with advanced medical resources, survival rates remain high.
Children with retinoblastoma benefit from personalized management of their disease and access to expert and multidisciplinary care. Chemotherapy remains a cornerstone of therapy, but its administration is complex, and there are many factors to consider.
The maxim “save the life, save the eye, save the sight,” remains the guiding principle in 2020 when managing retinoblastoma. This Focal Points module reviews the many intricacies of treating and managing this disease.
By completing this module, you will be able to:
Authors: Dan S. Gombos, MD; Jonathan W. Kim, MD; Matthew W. Wilson, MD
Focal Points issues review the most crucial advances and feature insights to help you integrate tested findings into your practice.
Subscribers receive 12 issues a year, plus access to the Focal Points digital archive.
This issue includes an audio version. To access the audio version of this module, scan the QR code in the print module or click the link within the digital module.
To access this issue from your laptop or desktop computer, log in to aao.org/myonlineproducts with your Academy username and password.
To access this issue from your smartphone or tablet, use the free AAO eBooks app. For eBook features, requirements and licensing, visit: aao.org/ebooks. Please allow up to 90 minutes for receiving an access key (via email) that will allow you to retrieve your eBook after purchase.
The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Academy of Ophthalmology designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.